Use of 7- (2-oxa-5,8-diazabicyclo [4.3.0] non-8-yl) -chinolon- -naphthyridoncarbonsäure and derivatives for the therapy of Helicobacter pylori infections and the gastroduodenal disorders associated therewith

The invention relates to the use of quinolone and naphthyridon carboxylic acid derivatives, which are substituted by a 2-oxa-5,8-diazabicyclo[4.3.0]-non-8-yl-radical in position seven, as well as to their pharmaceutically applicable hydrates and/or salts in the treatment of Helicobacter pylori infections and associated gastroduodenal diseases.